Home » AVI BioPharma’s Drug Candidate Receives European Orphan Drug Designation
AVI BioPharma’s Drug Candidate Receives European Orphan Drug Designation
AVI BioPharma, Inc., a developer of RNA-based drugs, announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency for AVI-5038, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy.
CNNMoney
CNNMoney
Upcoming Events
-
07May
-
14May
-
30May